



LET_LSE_PMS_0007/11/23

All correspondence should be addressed to the Director General

In reply, please quote

ZAMBIA MEDICINES REGULATORY AUTHORITY

PUBLIC NOTICE

Date: 7th November, 2023

To: Healthcare Professionals, Pharmaceutical Establishments, General Public

MEDICAL PRODUCT ALERT: SUPERLIFE STC30 - UNAPPROVED MEDICAL CLAIMS

The Zambia Medicines Regulatory Authority (ZAMRA) is a statutory body established under an Act of Parliament, the Medicines and Allied Substances Act No. 3 of 2013 of the laws of Zambia. The main mandate of ZAMRA is to regulate, and control the manufacture, importation, storage, distribution, supply, sale and use of medicines and allied substances for human and animal use for public health protection.

In light of the above, the Authority notes with sadness the flooding of social media with unapproved advertisements of **Superlife Total Care 30 (STC30) Supplements**. The product is registered as a nutritional supplement with the approved labelling that "**This product is not intended to diagnose, treat, cure or prevent any disease**".

According to the misleading information publicised by some unscrupulous individuals and entities, the supplement is claimed to be alternative medication for a wide range of disease conditions including fibroids, cancer, tuberculosis, arthritis, kidney disease, HIV/AIDS, impotence, gastritis, haemorrhoids, anti-ageing and brain damage. Others have claimed the supplement can cure over 200 unspecified diseases.

The Authority sternly warns individuals and entities involved in the illegal promotion and advertisement of this and similar herbal products to stop misleading the public by taking advantage of their health status. There is no clinical trial data that validates use of this supplement to diagnose, treat, cure or prevent any disease.

Further, the product is registered under the pharmacy "P" category and should only be sold from registered pharmaceutical outlets by qualified personnel. Providing unproven health products undermines public health and deprives unsuspecting people of their hard-earned income. It has potential to cause harm to consumers of such products.

We urge members of the public to desist from buying products which have not gone through any clinical trials for the purported claims and therefore, their safety and efficacy has not been proven.

Head Office

Plot No: 2350/M
Off Kenneth Kaunda International Airport Road
P.O. Box 31890, Lusaka, ZAMBIA
Tel: +260 211 432 350 /432 351
E-mail: pharmacy@zamra.co.zm

Report Adverse Reactions to:

Pharmacovigilance Unit, Lusaka
Tel: +260 211 432 356
E-mail: npvu@zamra.co.zm
Website: www.zamra.co.zm

The Authority has heightened surveillance of the illegal promotion of STC30 and similar products, and all perpetrators involved shall be prosecuted.

If you suffer any adverse drug reaction/event having used these products, you are advised to seek immediate medical advice and report the incident to the National Pharmacovigilance Unit at Zambia Medicines Regulatory Authority by phone: +260 211 432 356/+260 //956 521 094 or email address at: npvu@zamra.co.zm or pharmacy@zamra.co.zm.

Should the public need further clarification, please do not hesitate to contact the Secretariat.



Makomani Siyanga (Mr)
DIRECTOR-GENERAL